Enanta Pharmaceuticals’ (ENTA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report issued on Tuesday,Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00.

ENTA has been the subject of a number of other reports. JPMorgan Chase & Co. reduced their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research note on Tuesday, August 6th. Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ ENTA opened at $8.83 on Tuesday. The stock has a market cap of $187.11 million, a P/E ratio of -1.61 and a beta of 0.56. The firm’s 50-day simple moving average is $10.87 and its 200 day simple moving average is $12.28. Enanta Pharmaceuticals has a fifty-two week low of $8.00 and a fifty-two week high of $17.80.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ENTA. Allspring Global Investments Holdings LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter valued at $35,000. US Bancorp DE boosted its position in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in Enanta Pharmaceuticals in the 1st quarter worth about $118,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Enanta Pharmaceuticals during the 3rd quarter worth about $122,000. Finally, Quest Partners LLC lifted its stake in Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.